

1 **Posterior wall ablation by pulsed-field ablation – procedural safety,**
2 **efficacy and findings on redo procedures**

3
4 Thomas Kueffer MSc^{1,2}, Hildegard Tanner MD¹, Antonio Madaffari MD¹, Jens Seiler
5 MD¹, Andreas Haeblerlin MD^{1,2}, Jens Maurhofer MD¹, Fabian Noti MD¹, Claudia
6 Herrera MD¹, Gregor Thalmann MD¹, Nikola A. Kozhuharov MD¹, Tobias Reichlin
7 MD¹, Laurent Roten MD¹

8
9 ¹Department of Cardiology, Inselspital, Bern University Hospital, University of Bern,
10 Bern, Switzerland

11 ²ARTORG Center for Biomedical Engineering Research, University of Bern,
12 Switzerland

13 Running title: PWA by PFA

14
15 **Corresponding author**

16 Prof. Dr. med. Laurent Roten

17 Department of Cardiology, Inselspital – University Hospital Bern

18 Freiburgstrasse, CH-3010 Bern, Switzerland

19 Email: laurent.roten@insel.ch

20 Phone: +41 (0)31 632 52 63

1 **Data Availability Statement:** The data that support the findings of this study are
2 available from the corresponding author upon reasonable request.

3 **Funding:** none

4 **Disclosures**

5 A. Haeblerlin: Research grants from the Swiss National Science Foundation,
6 Innosuisse, the Swiss Heart Foundation, the University of Bern, the University
7 Hospital Bern, the Velux Foundation, the Hasler Foundation, the Swiss Heart
8 Rhythm Foundation, and the Novartis Research Foundation. He is Co-founder and
9 CEO of Act-Inno, a cardiovascular device testing company. He has received travel
10 fees/educational grants from Medtronic, Philips/Spectranetics and Cairdac without
11 impact on his personal remuneration.

12 L. Roten: speaker honoraria from Abbott/SJM, consulting honoraria from Medtronic,
13 research grant from the sitem insel support fund and research grant to the institution
14 from Medtronic.

15 T. Reichlin: Research grants from the Swiss National Science Foundation, the Swiss
16 Heart Foundation, the sitem insel support fund, Biotronik, Boston Scientific and
17 Medtronic, all for work outside the submitted study. Speaker/consulting honoraria or
18 travel support from Abbott/SJM, Bayer, Biosense-Webster, Biotronik, Boston-
19 Scientific, Medtronic and Pfizer-BMS, all for work outside the submitted study.
20 Support for his institution's fellowship program from Abbott/SJM, Biosense-Webster,
21 Biotronik, Boston-Scientific and Medtronic for work outside the submitted study.

22 F. Noti: Medtronic, Abbott: Travel fees, speaker fees, educational grant; Boston
23 Scientific, Philips Spectranetics: Travel fees, educational grant; Biotronik:
24 Institutional grant all for work outside the submitted study.

25 N. Kozhuharov: Research grants from the Swiss National Science Foundation (grant
26 Nr P400PM-194477 and grant Nr P5R5PM_210856), Gottfried und Julia Bangerter-
27 Rhyner-Stiftung, Freiwillige Akademische Gesellschaft, L. & Th. La Roche Stiftung,
28 and the European Society of Cardiology.

29 J. Seiler: The spouse of Dr Seiler is an employee of Boston Scientific and stock
30 owner of Boston Scientific and Abbott.

31 T. Küffer: Research grant from the Swiss Heart Foundation.

32 All other authors report no conflicts of interest related to this paper.

33

34

1 **Abstract: 247 words**

2 **Background** The left atrial posterior wall is a potential ablation target in patients with
3 recurrent atrial fibrillation despite durable pulmonary vein isolation or in patients with
4 roof-dependent atrial tachycardia (AT). Pulsed-field ablation (PFA) offers efficient
5 and safe posterior wall ablation (PWA), but available data is scarce.

6 **Methods** Consecutive patients undergoing PWA using PFA were included. PWA
7 was performed using a pentaspline PFA catheter and verified by 3D-electroanatomic
8 mapping. Follow-up was performed using 7-day Holter-ECGs 3, 6, and 12 months
9 after ablation. Recurrence of any atrial arrhythmia lasting more than 30 seconds was
10 defined as failure. Lesion durability was assessed during redo procedures.


11 **Results** PWA was performed in 215 patients (70% males, median age 70 [IQR 61-
12 75] years, 67% redo procedures) and was successful in all patients (100%) by
13 applying a median of 36 (IQR 32-44) PFA lesions. Severe adverse events were
14 cardiac tamponade and vascular access complication in one patient each (0.9%).
15 Median follow-up was 7.3 (IQR 5.0-11.8) months. One-year arrhythmia-free outcome
16 in Kaplan-Meier analysis was 53%. A redo procedure was performed in 26 patients
17 (12%) after a median of 6.9 (IQR 2.4-11) months and showed durable PWA in 22
18 patients (85%) with only minor lesion regression. Among 4 patients with posterior
19 wall reconnection, 3 (75%) presented with roof-dependent AT.

20 **Conclusion** PWA with this pentaspline PFA catheter can be safely and efficiently
21 performed with a high durability observed during redo procedures. The added value
22 of durable PWA for the treatment of atrial fibrillation remains to be evaluated.

23
24 **Keywords:** Atrial fibrillation, pulsed-field ablation, reconnection, pulmonary vein
25 isolation

26

1 Graphical Abstract



2

1 Introduction

2 Pulmonary vein isolation (PVI) is the treatment of choice in the interventional
3 management of atrial fibrillation (AF).¹ Despite successful, durable PVI, AF recurs in
4 10-15% of patients with paroxysmal AF and even more frequently in patients with
5 persistent AF.² In these patients, ablation of additional sites harboring AF triggers or
6 perpetuators is necessary. The left atrial (LA) posterior wall (PW) is one of the main
7 targets beyond PVI, as it shares a common embryologic origin with the pulmonary
8 veins and hence is thought to be arrhythmogenic.^{3, 4} The posterior wall may also
9 have to be ablated in patients with a roof-dependent LA tachycardia.⁵

10 So far, randomized controlled trials adding posterior wall isolation (PWI) to PVI in
11 patients with persistent AF yielded conflicting results. While some smaller studies
12 showed a benefit⁶⁻⁸, both the POBI-AF study nor the recent CAPLA trial did.^{9, 10}
13 Importantly, all these studies used thermal ablation technologies for PWI which has
14 significant limitations: 1) failure to complete PWI in a significant number of cases; 2)
15 reconnection of PWI during follow-up; and 3) limitation of energy delivery on the
16 posterior wall due to safety concerns, in particular damage to the adjacent
17 esophagus. Hence, the true value of PWI for treating atrial fibrillation has yet to be
18 established using efficient and safe tools for complete and durable PWI.

19 Pulsed-field ablation (PFA) is a non-thermal ablation technology which specifically
20 targets the cardiac muscle fibers and leaves surrounding structures unharmed. It
21 applies microsecond-scale pulses that disrupt cell membranes, leading to cell death.
22 The first PFA catheter gained CE approval in January 2021. This PFA catheter was
23 designed for PVI and can change its configuration from a basket to a flower
24 configuration. In its flower configuration, the catheter is well-suited for posterior wall

1 ablation (PWA) and may overcome the limitations of PWI by thermal ablation.

2 **Methods**

3 **Study population**

4 All consecutive patients with paroxysmal AF, persistent AF, or LA tachycardia
5 undergoing an LA ablation procedure including PWA using the FARAPULSE PFA
6 system (Boston Scientific, United States) at the Bern University Hospital until the end
7 of the year 2022 were analyzed. All patients were enrolled in a prospective
8 institutional ablation registry. The registry was approved by the local ethics
9 committee and carried out in accordance with the declaration of Helsinki. The
10 authors had full access to the data and bear full responsibility for its accuracy.

11 **Ablation procedure**

12 PWA was performed using the PFA platform consisting of a generator, a long
13 steerable sheath, and an ablation catheter (FARASTAR, FARADRIVE, and
14 FARAWAVE, Boston Scientific, Menlo Park, CA, USA). The generator of the
15 platform delivers high-intensity, bipolar and biphasic electric pulses to the catheter
16 electrodes, creating an electric field that disrupts the membranes of adjacent cells
17 and leads to irreversible electroporation and cell death.¹¹

18 Prior to the procedure, patients underwent trans-esophageal echocardiography and
19 computed tomography to exclude intracardiac thrombi and to obtain a detailed
20 understanding of the left atrial anatomy. Deep conscious sedation using propofol and
21 fentanyl was used, guided by a physician-led, nurse-administered protocol, while
22 patients with a high risk of sedation complications underwent general anesthesia.¹²
23 Left atrial access was obtained by fluoroscopy-guided transseptal puncture either
24 using a standard SL1 sheath, followed by an exchange to the 13F FARADRIVE

1 sheath, or through a direct puncture using the 13F sheath, depending on the
2 physician's preference.¹³

3 In the majority of patients, a 3D electro-anatomical mapping (3D-EAM) system
4 (CARTO 3, Biosense Webster, Irvine, CA, USA) and a high-density multi-electrode
5 mapping catheter (PENTARAY or OCTARAY, Biosense Webster, Irvine, CA, USA)
6 were used before PWA to identify previously isolated PVs, as applicable, and to
7 characterize left atrial substrate. Before PWA, PVI was performed as necessary with
8 the PFA system and according to standard practice.¹⁴ PWA was performed in two
9 steps: First, posterior anchor lesions were applied to each vein with the device in
10 flower configuration and the guidewire placed in a vein, applying strong posterior
11 torque to the sheath (**Figure 1A**). For each vein, four anchor lesions were placed,
12 and the catheter rotated by 30° after the first two applications. Second, the guidewire
13 was retracted and pairwise, overlapping lesions were placed without catheter
14 rotation between applications, covering the entire posterior wall from the upper end
15 of the superior veins to the lower end of the inferior veins (**Figure 1B**). Voltage
16 amplitude for PFA was changed from 1.9 kV to 2.0 kV following the recommendation
17 of the manufacturer in September 2021. Catheter size selection (31 vs 35 mm) was
18 at the discretion of the operator.

19 Following PWA, a detailed 3D-EAM was again generated with the multi-spline
20 catheter and additional PFA lesions were applied as necessary to complete PWA.
21 Depending on the individual case, additional ablation of a posterior or anterior mitral
22 isthmus line, LA substrate ablation, ablation of the cavotricuspid isthmus, isolation of
23 the superior vena cava, and right atrial substrate ablation were performed using
24 either PFA or radiofrequency ablation.

25 **Follow-up**

1 Patients were followed with 7-day Holter ECGs 3, 6, and 12 months after the ablation
2 procedure. Recurrence was defined as any atrial tachyarrhythmia (AF, atrial flutter,
3 or AT) lasting longer than 30 seconds between days 91 and 365 post-ablation of the
4 posterior wall. In case of a symptomatic recurrence, further options were discussed
5 with the patient and a redo procedure offered.

6 **Mapping protocol at repeat ablation**

7 All repeat ablation procedures were again performed using a 3D-EAM system and a
8 high-density multi-electrode mapping catheter. 3D-EAM was used to identify the
9 tachycardia mechanism, lesion durability and regression, and to identify LA
10 substrate. Pre-ablation maps of the redo procedure were compared to post-ablation
11 maps of the previous procedure.

12 Based on the high-density 3D maps, the target lesion set for the repeat procedure
13 was determined and additional ablation was performed with either point-by-point
14 radiofrequency ablation or PFA, according to the operator's preference.

15 **Statistical analysis**

16 Continuous data are shown as mean (\pm standard deviation) or median (interquartile
17 range) as appropriate and were compared with the Mann-Whitney-U, the t-test, or
18 the Kruskal-Wallis test, as appropriate. Categorical variables were reported as
19 counts (percentage) and compared with a Pearson chi-square test or the Fisher
20 exact test, as appropriate. Kaplan-Meier analyses with log-rank test was performed
21 for arrhythmia recurrence. The statistical analysis was conducted using R 4.2.2 (R
22 Core Team, Vienna, Austria). A two-sided p-value of ≤ 0.05 was considered
23 significant.

24

1 Results

2 Patient population and ablation history

3 From May 2021 to December 2022, 215 patients underwent an LA ablation
4 procedure including PWA using PFA at our institution. Of these, 64 (30%) were
5 female, median age was 69 (IQR 61-75) years and median CHADS-VASC score 2
6 (IQR 1-4). PWA was targeted during a first procedure in 70 (33%) patients and in
7 145 (66%) during a redo procedure. The arrhythmia that led to the first left atrial
8 ablation procedure was persistent AF in 151 (70%), paroxysmal AF in 56 (26%), and
9 left AT in 8 (4%). Patients coming for a redo procedure had a median of 1 previous
10 procedures (IQR 1-2). Baseline patient characteristic and details about previous
11 ablation targets can be found in **Table 1**.

12 Ablation procedure including PWA

13 Indication to perform PWA was the presence of PW scar in 79 patients (37%), no
14 PW scar with either recurrence despite durable PVI or as a first-line treatment
15 decision based on patient history in 56 (26%), LA tachycardia in 62 (29%), and
16 anatomical reasons (narrow, remaining gap of tissue on the posterior wall after PVI
17 using PFA; or anomalous accessory roof or posterior pulmonary vein) in 18 (8%)
18 **(Figure 2)**. The 31 mm sized PFA device was used in 200 (93%) of patients. A high-
19 density map was generated prior to PWA in 191 (89%) of patients. In the remaining
20 cases, PWA was performed solely using fluoroscopy for catheter guidance. In all
21 patients, 16 anchor lesions were applied (4 per vein) plus a median number of 20
22 (IQR 16-28) PFA lesions to complete PWA. High-density maps showed successful
23 PWA in 215/215 (100%) patients. No radiofrequency ablation was necessary to
24 complete PWA in any patient. Additional ablation targets besides PWA in the same

1 procedure were left to the discretion of the operator and included a posterior mitral
2 isthmus line in 14 patients (7%), anterior mitral isthmus line in 28 (13%), LA
3 substrate ablation in 20 (9%), ablation of the cava-tricuspid isthmus in 37 (17%), and
4 isolation of the superior vena cava in 7 (3%). The Supplementary Table describes
5 indications for PWA and additional ablation targets in patients with paroxysmal or
6 persistent AF or left atrial tachycardia as the index arrhythmia for the first left atrial
7 ablation procedure. Pericardial effusion requiring pericardiocentesis occurred in one
8 patient and one patient had a small arterio-venous fistula at the puncture site, which
9 was successfully managed by targeted compression. In the 43 patients undergoing a
10 first left atrial ablation procedure including PVI and PWA, median procedure duration
11 was 104 (IQR 79-128) minutes and median fluoroscopy time 24 (17-30) minutes.
12 Procedural characteristics and lesion sets can be found in **Table 2 and Figure 2**.

13 **Follow-up and recurrence**

14 The median follow-up time after PWA was 7.3 (IQR 5.0-11.8) months. An arrhythmia
15 recurred in 78 patients (37%) a median of 5.8 (IQR 3.7-8.8) months after PWA.
16 Arrhythmia recurrence was AT in 34 patients (46%), persistent AF in 23 (31%), and
17 paroxysmal AF in 17 (23%). K-M analysis showed a freedom from any atrial
18 arrhythmia of 79% after 6 months and 53% after 12 months in the complete cohort.
19 There was no difference in freedom from arrhythmia between persistent or
20 paroxysmal AF (56% vs. 49%, $p=0.4$) after one year. In patients treated for persistent
21 AF, the presence of PW scar did not influence freedom from arrhythmia (45% vs.
22 65%, $p=0.099$). Similarly, PWA during the first vs. PWA during a redo procedure did
23 not affect freedom from arrhythmia in patients treated for persistent AF (40% vs.
24 55%, $p=0.17$) (**Table 2, Figure 4**).

1 Findings on redo procedures

2 26/68 (38%) patients with arrhythmia recurrence underwent an LA redo ablation
3 procedure, 5 (19%) for AF and 21 (81%) for AT. Tachycardia mechanism for the
4 latter was roof-dependent flutter in 3 (12%) cases, perimitral flutter in 4 (15%) cases,
5 multiple LA AT's in 3 (12%) cases, antral, scar-dependent reentry in 3 (12%) cases,
6 CTI, biatrial flutter, and an unidentified AT in 1 case each, and no AT could be
7 induced in the remaining 5 cases. Details on redo ablation can be found in **Table 3**.
8 High-density 3D-EAM identified 22/26 (85%) of the posterior walls with durable
9 isolation, i.e. no reconnection across the posterior wall. In cases without
10 reconnection the minimal width of the ablated area measured from the inferior to the
11 superior scar border was reduced from 44 mm (IQR 40-50) to 41 mm (IQR 36-46). A
12 large lesion regression of >10 mm was found in 4 (15%) cases (see Supplement). In
13 these, the scar border distance regressed from 50 mm (IQR 47-53) to 29 mm (IQR
14 26-30). Importantly, these 4 cases still showed conduction block across the posterior
15 wall, preventing PW-dependent AT. In 4/26 cases (15%) the PW was no longer
16 isolated, allowing for conduction across it. In 3 of these cases (75%), PW-dependent
17 AT was identified and the remaining patient presented with perimitral AT. No
18 procedural adverse events occurred during the redo procedures. Maps acquired
19 during redo procedures and corresponding post-ablation maps from the index
20 procedure can be found in the **Supplement**.

21

1 Discussion

2 In this large study of 215 consecutive patients undergoing PWA using a median of
3 36 PFA applications our main findings are:

- 4 1. PWA using PFA was safe, efficient and effective.
- 5 2. Remapping in patients with arrhythmia recurrence showed durable posterior
6 wall isolation in 85% with only minor lesion regression.
- 7 3. The overall arrhythmia recurrence rate after 12 months was 47%.
- 8 4. A roof-dependent atrial tachycardia occurred in 75% of patients with posterior
9 wall reconnection.

10 **Acute results**

11 Our study shows that by using this pentaspline PFA device, we can achieve fast and
12 effective, acute, complete posterior wall ablation in all patients. Similarly, the pre-
13 market PersAFOne trial reported successful PWA in 25/25 (100%) patients.¹⁵ In
14 comparison, acute posterior wall isolation by radiofrequency ablation was achieved
15 in only 86.5% of patients in the recently published CAPLA trial, and half of the
16 patients required additional ablation within the posterior wall to complete PWI.¹⁰ Pak
17 et al. reported successful PWI in 94% of patients with radiofrequency ablation and
18 used a protocol that mandated voltage map-guided ablation of any remnant atrial
19 potentials on the posterior wall as well as an electrical exit block as an endpoint. In
20 the later POBI-AF trial by the same group and using the same protocol and
21 endpoints, complete PWI was also reported in all patients.⁹ With cryoballoon ablation
22 of the posterior wall, Ahn et al. described successful PWI in 62% of the patients
23 only.⁶ In another trial comparing PVI with PVI plus PWI, Aryana et al. reported

1 successful PVI in all 55 patients using cryoballoon ablation, but touch-up
2 radiofrequency ablation was necessary in almost half of the patients.⁷

3 The pentaspline PFA catheter used in our study, in its flower pose, is ideally suited
4 for PWA and highly effective without the need for touch-up thermal ablation.
5 Importantly, it does require a large number of overlapping applications to completely
6 cover the posterior wall and good tissue contact has to be ensured to achieve
7 durable lesions. To this end, the integration and visualization of the PFA catheter into
8 a 3D-EAM is very helpful, although PWA can also be achieved by fluoroscopy
9 guidance alone. In our workflow, we always start PWA by applying 4 “anchor” lesions
10 on the posterior aspect of each pulmonary vein. If combined with PVI and to shorten
11 procedure duration, these “anchor” lesions can be applied after the standard 4+4
12 PFA applications per vein, with the guidewire still within the pulmonary vein. After
13 completion of the “anchor” lesions and retraction of the guidewire, two to three lines
14 (depending on left atrial size) of PFA lesions are applied to cover the tissue in-
15 between the left- and right-sided “anchor” lesions.

16 **Procedural characteristics**

17 With this technique, median procedure duration for PVI plus PWA in patients
18 undergoing a first left atrial ablation procedure was 104 (IQR 49-128) minutes. In
19 comparison, median procedure duration in the CAPLA trial and the POBI-AF trial for
20 PVI plus PWA were 142 minutes and 227 minutes, respectively.^{9, 10} With cryoballoon
21 ablation, PVI plus PWA required a mean of 168 minutes in the study by Aryana.⁷
22 Therefore, PWA with PFA offers clearly improved procedural efficiency compared to
23 thermal ablation technologies both in terms of acute success rate as well as
24 procedure duration.

1 Adverse events were low in our study and well within rates reported by others.¹⁶
2 While thermal complications like esophageal damage or phrenic nerve palsy are less
3 probable with PFA, mechanical complications like pericardial effusions and vascular
4 injuries can still occur. This is also true for air embolism or left atrial clot formation.¹⁷
5 However, a considerably larger number of cases will have to be treated with PFA, in
6 particular including PWA, to give the final “all-clear” regarding esophageal damage
7 caused by PFA. In the meantime, our study provides reassuring results by including
8 the largest number of cases to date.

9

10 **Recurrence and durability**

11 Arrhythmia recurrence after one year was still high in our population, and in the
12 range reported by the CAPLA trial.¹⁰ However, we included a case mix of patients,
13 many of whom had already failed several previous ablation procedures and most of
14 them had persistent AF and advanced atrial cardiomyopathy. Hence, we cannot
15 draw any firm conclusions regarding the value of PWA to avoid arrhythmia
16 recurrence and randomized controlled trials with more strict inclusion criteria that
17 evaluate the benefit of PVI plus PWA by PFA as compared to PVI alone will be
18 needed.

19 For PWA to be successful, lesion durability is a key factor. In the PersAFOne study,
20 all patients underwent a redo procedure after PWA by PFA and no reconnection was
21 reported.¹⁵ Without mandated redo procedures, rates of durably isolated pulmonary
22 veins as well as durably isolated posterior walls are generally underestimated
23 because of a selection bias. This is because only patients with arrhythmia recurrence
24 and among those only patients with sufficient arrhythmia burden will undergo a redo
25 ablation procedure. In our study, 12% of patients had a redo procedure which is

1 similar to the 10% in both the CAPLA trial and the POBI-AF trial.^{9, 10} Durability of PW
2 isolation was found in 31.2% of patients in CAPLA, and in 50% in POBI-AF. After
3 PWA using PFA, we observed durable PWA in 85% of patients, and with only minor
4 lesion regression. Although such indirect comparisons need to be taken with caution,
5 it is remarkable that such low reconnection rates can be achieved with the first
6 clinically available PFA catheter, which was neither optimized for PWA nor offers
7 intrinsic 3D mapping integration. The latter will likely further ameliorate lesion
8 precision and durability if feedback on tissue contact can be provided, as sufficient
9 tissue contact is probably a key factor for durable lesions. Nevertheless, lesion
10 durability is paramount for PWA by PFA, given that 75% of the patients with a
11 reconnected posterior wall had roof-dependent AT in our study.

12 **Limitations**

13 The following limitations of the present study merit consideration. First, this is a
14 retrospective observational single-center study. In particular, we did not have a
15 specific ablation strategy. The decision to perform PWA and to add other ablation
16 targets was at the discretion of the operator, as was the endpoint of the ablation
17 procedure. Our results must be interpreted in conjunction with similar data reported
18 from other groups. Second, only 26/68 (38%) patients with recurrence of an
19 arrhythmia underwent repeat ablation, which might have introduced a selection bias.
20 Third, median follow-up time after PWA was only 7 months and longer-term follow-up
21 data is needed to confirm our results. Finally, due to the low rate of reconnected
22 posterior walls, a meaningful analysis regarding predictors of posterior wall
23 reconnection was not possible in our study and larger data sets are necessary.

24 **Conclusion**

1 PWA with this pentaspline PFA catheter is safe, effective and efficient both with
2 regard to the completeness of PWA and procedure duration. Posterior wall ablation
3 is durable with only minor lesion regression in the majority of patients with arrhythmia
4 recurrence. Most patients with posterior wall reconnection present with PW-
5 dependent AT. The added value of durable PWA for the treatment of atrial fibrillation
6 remains to be evaluated.

ACCEPTED MANUSCRIPT

1 References

- 2 1. Metzner A, Kuck KH and Chun JKR. What we have learned: is pulmonary vein
3 isolation still the cornerstone of atrial fibrillation ablation? *Europace*. 2022;24:ii8-ii13.
- 4 2. Sorensen SK, Johannessen A, Worck R, Hansen ML and Hansen J. Radiofrequency
5 Versus Cryoballoon Catheter Ablation for Paroxysmal Atrial Fibrillation: Durability of
6 Pulmonary Vein Isolation and Effect on Atrial Fibrillation Burden: The RACE-AF Randomized
7 Controlled Trial. *Circ Arrhythm Electrophysiol*. 2021;14:e009573.
- 8 3. Jongbloed MR, Schalij MJ, Poelmann RE, Blom NA, Fekkes ML, Wang Z, Fishman
9 GI and Gittenberger-De Groot AC. Embryonic conduction tissue: a spatial correlation with
10 adult arrhythmogenic areas. *J Cardiovasc Electrophysiol*. 2004;15:349-55.
- 11 4. de Groot N, van der Does L, Yaksh A, Lanfers E, Teuwen C, Knops P, van de
12 Woestijne P, Bekkers J, Kik C, Bogers A and Allessie M. Direct Proof of Endo-Epicardial
13 Asynchrony of the Atrial Wall During Atrial Fibrillation in Humans. *Circ Arrhythm
14 Electrophysiol*. 2016;9:e003648.
- 15 5. Pambrun T, Duchateau J, Delgove A, Denis A, Constantin M, Ramirez FD, Chauvel
16 R, Tixier R, Welte N, Andre C, Nakashima T, Nakatani Y, Kamakura T, Takagi T, Krisai P,
17 Cheniti G, Vlachos K, Bourier F, Takigawa M, Kitamura T, Frontera A, Sacher F, Hocini M,
18 Jais P, Haissaguerre M, Walton RD and Derval N. Epicardial course of the septopulmonary
19 bundle: Anatomical considerations and clinical implications for roof line completion. *Heart
20 Rhythm*. 2021;18:349-357.
- 21 6. Ahn J, Shin DG, Han SJ and Lim HE. Does isolation of the left atrial posterior wall
22 using cryoballoon ablation improve clinical outcomes in patients with persistent atrial
23 fibrillation? A prospective randomized controlled trial. *Europace*. 2022;24:1093-1101.
- 24 7. Aryana A, Allen SL, Pujara DK, Bowers MR, O'Neill PG, Yamauchi Y, Shigeta T,
25 Vierra EC, Okishige K and Natale A. Concomitant Pulmonary Vein and Posterior Wall
26 Isolation Using Cryoballoon With Adjunct Radiofrequency in Persistent Atrial Fibrillation.
27 *JACC Clin Electrophysiol*. 2021;7:187-196.
- 28 8. Kim JS, Shin SY, Na JO, Choi CU, Kim SH, Kim JW, Kim EJ, Rha SW, Park CG, Seo
29 HS, Oh DJ, Hwang C and Lim HE. Does isolation of the left atrial posterior wall improve
30 clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation?: A
31 prospective randomized clinical trial. *Int J Cardiol*. 2015;181:277-83.
- 32 9. Lee JM, Shim J, Park J, Yu HT, Kim TH, Park JK, Uhm JS, Kim JB, Joung B, Lee
33 MH, Kim YH, Pak HN and Investigators P-A. The Electrical Isolation of the Left Atrial
34 Posterior Wall in Catheter Ablation of Persistent Atrial Fibrillation. *JACC Clin Electrophysiol*.
35 2019;5:1253-1261.
- 36 10. Kistler PM, Chieng D, Sugumar H, Ling LH, Segan L, Azzopardi S, Al-Kaisey A,
37 Parameswaran R, Anderson RD, Hawson J, Prabhu S, Voskoboinik A, Wong G, Morton JB,
38 Pathik B, McLellan AJ, Lee G, Wong M, Finch S, Pathak RK, Raja DC, Sterns L, Ginks M,
39 Reid CM, Sanders P and Kalman JM. Effect of Catheter Ablation Using Pulmonary Vein
40 Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence
41 in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial. *JAMA*.
42 2023;329:127-135.
- 43 11. Maor E, Sugrue A, Witt C, Vaidya VR, DeSimone CV, Asirvatham SJ and Kapa S.
44 Pulsed electric fields for cardiac ablation and beyond: A state-of-the-art review. *Heart
45 Rhythm*. 2019;16:1112-1120.
- 46 12. Servatius H, Kuffer T, Baldinger SH, Asatryan B, Seiler J, Tanner H, Novak J, Lam A,
47 Noti F, Haerberlin A, Madaffari A, Sweda R, Muhl A, Branca M, Dutschler S, Erdoes G,
48 Stuber F, Theiler L, Reichlin T and Roten L. Dexmedetomidine versus propofol for operator-
49 directed nurse-administered procedural sedation during catheter ablation of atrial fibrillation:
50 A randomized controlled study. *Heart Rhythm*. 2022;19:691-700.
- 51 13. Kueffer T, Madaffari A, Thalmann G, Muhl A, Galuszka O, Baldinger S, Seiler J,
52 Tanner H, Kobza R, Roten L, Berte B and Reichlin T. Eliminating transeptal sheath

- 1 exchange for pulsed field ablation procedures using a direct over-the-needle transeptal
2 access with the Faradrive sheath. *Europace*. 2023;25:1500-1502.
- 3 14. Kueffer T, Baldinger SH, Servatius H, Madaffari A, Seiler J, Mühl A, Franzeck F,
4 Thalmann G, Asatryan B, Haeberlin A, Noti F, Tanner H, Roten L and Reichlin T. Validation
5 of a multipolar pulsed-field ablation catheter for endpoint assessment in pulmonary vein
6 isolation procedures. *EP Europace*. 2022;24:1248-1255.
- 7 15. Reddy VY, Anic A, Koruth J, Petru J, Funasako M, Minami K, Breskovic T, Sikiric I,
8 Dukkupati SR, Kawamura I and Neuzil P. Pulsed Field Ablation in Patients With Persistent
9 Atrial Fibrillation. *J Am Coll Cardiol*. 2020;76:1068-1080.
- 10 16. Benali K, Khairy P, Hammache N, Petzl A, Da Costa A, Verma A, Andrade JG and
11 Macle L. Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation. *J Am*
12 *Coll Cardiol*. 2023;81:2089-2099.
- 13 17. Cochet H, Nakatani Y, Sridi-Cheniti S, Cheniti G, Ramirez FD, Nakashima T, Eggert
14 C, Schneider C, Viswanathan R, Derval N, Duchateau J, Pambrun T, Chauvel R, Reddy VY,
15 Montaudon M, Laurent F, Sacher F, Hocini M, Haissaguerre M and Jais P. Pulsed field
16 ablation selectively spares the oesophagus during pulmonary vein isolation for atrial
17 fibrillation. *Europace*. 2021;23:1391-1399.

18
19

ACCEPTED MANUSCRIPT

1 Tables

2 Table 1

Table 1. Baseline patient characteristics

Variable	Overall
N	215
Age - years	69.5 [61.3, 75.3]
Sex, male	151 (70.2)
Body-mass index - kg/m ²	27.7 [24.6, 32.5]
Primary AF type - no. (%)	
Persistent	151 (70.2)
Paroxysmal	56 (26.0)
AT	8 (3.7)
Duration of persistent AF - months	26.0 [6.0, 67.5]
CHA ₂ DS ₂ -VASc score	2.0 [1.0, 4.0]
Redo LA ablation procedure - no. (%)	145 (67.4)
Ablation technology of the previous intervention - no. (%)	
RFA	87 (60.0)
CBA	30 (20.7)
PFA	22 (15.2)
Surgical	6 (4.1)
Previous DCCV - no. (%)	107 (49.8)
Hypertension - no. (%)	133 (61.9)
Previous heart failure - no (%)	51 (23.7)
Diabetes - no. (%)	28 (13.0)
Previous stroke or TIA - no. (%)	16 (7.4)
Chronic obstructive pulmonary disease - no. (%)	15 (7.0)
Sleep apnea - no. (%)	36 (16.7)
Class III AAD - no. (%)	70 (32.6)
Left atrial volume index - mL/m ²	46.5 [37.0, 55.2]
Left ventricular ejection fraction - %	55.0 [45.0, 60.0]
Left common ostium - no. (%)	40 (18.6)

Numbers are median [IQR] unless otherwise noted. AAD = Antiarrhythmic drug; AF = Atrial fibrillation; AT = Atrial tachycardia; CBA = Cryoballoon ablation; DCCV = Direct-current cardioversion; IQR = interquartile range; LA = Left atrial; PFA = Pulsed-field ablation; RFA = Radiofrequency ablation; TIA = Transient ischemic attack.

3

1

2 *Table 2***Table 2. Procedural data, complications, and follow-up**

Indication for PWA	Overall	PW scar	LA Flutter	No PW scar	Anatomy	p
N	215	79	62	56	18	
Procedure						
Redo procedure - no. (%)	145 (67.4)	55 (69.6)	44 (71.0)	37 (66.1)	9 (50.0)	0.382
Pre-map (3D-EAM) - no. (%)	192 (89.3)	79 (100.0)	61 (98.4)	36 (64.3)	16 (88.9)	<0.001
31 mm device	200 (93.0)	70 (88.6)	58 (93.5)	55 (98.2)	17 (94.4)	0.189
Number of PFA applications for anchor lesions	16.0 [16.0, 16.0]	16.0 [16.0, 16.0]	16.0 [16.0, 16.0]	16.0 [16.0, 16.0]	16.0 [16.0, 16.0]	-
Number of PFA applications for PWA	20.0 [16.0, 28.0]	20.0 [18.0, 28.0]	20.0 [16.0, 22.0]	24.0 [20.0, 32.0]	16.0 [12.5, 19.0]	<0.001
Total number of PFA applications for PWA	36.0 [32.0, 44.0]	36.0 [34.0, 44.0]	36.0 [32.0, 38.0]	40.0 [36.0, 48.0]	32.0 [28.5, 35.0]	<0.001
Successful PWA with PFA alone - no. (%)	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	-
Posterior MIL - no. (%)	14 (6.5)	1 (1.3)	12 (19.4)	1 (1.8)	0	<0.001
Anterior MIL - no. (%)	28 (13.0)	6 (7.6)	21 (33.9)	0	1 (5.6)	<0.001
LA substrate ablation - no. (%)	20 (9.3)	4 (5.1)	13 (21.0)	3 (5.4)	0	0.002
CTI ablation using RFA - no. (%)	37 (17.2)	13 (16.5)	16 (25.8)	7 (12.5)	1 (5.6)	0.120
SVC isolation - no. (%)	7 (3.3)	3 (3.8)	3 (4.8)	1 (1.8)	0	0.669
Procedure time - min	120.0 [88.0, 156.0]	117.0 [88.0, 138.5]	162.5 [132.5, 204.2]	95.0 [76.8, 123.2]	97.5 [78.2, 110.8]	<0.001
Fluoroscopy time - min	21.0 [15.0, 29.1]	20.0 [14.9, 28.6]	24.6 [17.2, 36.0]	19.2 [13.2, 24.1]	23.7 [18.9, 26.5]	0.011
Fluoroscopy dose - Gy cm^2	6.4 [3.1, 11.8]	6.5 [2.9, 13.0]	6.7 [3.3, 13.1]	6.3 [3.4, 10.4]	5.6 [3.0, 7.6]	0.808
Complications						
Cardiac tamponade - no. (%)	1 (0.5)	1 (1.3)	0	0	0	0.630
Vascular complication - no. (%)	1 (0.5)	1 (1.3)	0	0	0	0.630
Cerebral complication - no. (%)	0	0	0	0	0	-
Esophageal complication - no. (%)	0	0	0	0	0	-
Phrenic paresis - no. (%)	0	0	0	0	0	-
Follow-up						
Follow-up - months	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	1.0 [1.0, 1.0]	-
Follow-up - months	7.3 [5.0, 11.8]	7.7 [5.0, 11.7]	5.9 [3.4, 11.9]	7.9 [6.0, 11.8]	9.4 [5.9, 11.5]	0.267
Recurrence of atrial arrhythmia - no. (%)	78 (36.8)	33 (42.9)	24 (39.3)	18 (32.1)	3 (16.7)	0.169
Time to recurrence - months	5.8 [3.7, 8.8]	6.2 [3.7, 7.9]	4.8 [3.2, 6.6]	7.7 [6.3, 10.8]	5.4 [4.2, 7.9]	0.014
Type of recurrence - no. (%)						0.001

Table 2. Procedural data, complications, and follow-up

Indication for PWA	Overall	PW scar	LA Flutter	No PW scar	Anatomy	p
AT	34 (45.9)	13 (39.4)	19 (82.6)	1 (6.7)	1 (33.3)	
Paroxysmal AF	17 (23.0)	7 (21.2)	3 (13.0)	6 (40.0)	1 (33.3)	
Persistent AF	23 (31.1)	13 (39.4)	1 (4.3)	8 (53.3)	1 (33.3)	
LA redo procedure - no. (%)	26 (12.1)	10 (12.7)	13 (21.0)	3 (5.4)	0	0.024
Time to redo procedure - months	6.9 [2.4, 11.0]	8.0 [1.2, 10.8]	6.4 [4.6, 11.9]	6.9 [0.0, 7.1]	0	0.193

Numbers are median [IQR] unless otherwise noted. 3D-EAM = 3D-Electroanatomical mapping; AF = Atrial fibrillation; AT = Atrial tachycardia; CTI = Cavotricuspid isthmus; IQR = interquartile range; MIL = Mitral isthmus line; PFA = Pulsed-field ablation; PWA = Posterior wall ablation; RFA = Radiofrequency ablation; SVC = Superior vena cava;

1 *Table 3***Table 3. Rredo procedure**

Variable	Overall	Durable PWA	Non-durable PWA	p
n	26	22	4	
Time to recurrence - months	6.0 [3.8, 8.9]	6.0 [4.4, 8.9]	6.3 [3.5, 8.9]	0.696
Type of arrhythmia - no. (%)				0.570
AT	21 (80.8)	17 (77.3)	4 (100.0)	
Paroxysmal AF	1 (3.8)	1 (4.5)	0	
Persistent AF	4 (15.4)	4 (18.2)	0	
Time to redo procedure - months	8.8 [6.4, 11.8]	8.0 [6.4, 11.5]	10.7 [8.0, 11.9]	0.749
Lesion regression - mm	2.6 [0.1, 7.2]	2.6 [0.1, 7.2]	-	-

Numbers are median [IQR] unless otherwise noted. AF = Atrial fibrillation; AT = Atrial tachycardia; IQR = interquartile range; PWA = Posterior wall ablation.

2

3

4

ACCEPTED MANUSCRIPT

1 Figure legends

2 *Figure 1: Workflow for posterior wall ablation using pulsed field ablation*

3 After pulmonary vein isolation, four additional anchor lesions per vein in flower
4 configuration and with posterior torque on the FARADrive sheath were placed to
5 extend the lesion further into the posterior wall (A). Successive ablation of the
6 posterior wall was achieved by targeting the entire space between the left and the
7 right pulmonary veins with pairwise, overlapping applications and without rotation of
8 the device. PW = Posterior wall

9 *Figure 2: Indications for posterior wall ablation*

10 Indication to perform posterior wall ablation was either: A) Presence of posterior wall
11 scar, identified by 3D-EAM; B) Left atrial tachycardia; C) No posterior wall scar*:
12 PWA was performed either due to recurrence despite durable PVI or as a first-line
13 treatment strategy based on the patient's medical history; and D) Anatomical
14 reasons[†]: PWA was performed either due to a narrow surviving channel after PVI or
15 due to an anomalous roof vein. 3D-EAM = 3D electro-anatomical mapping; LA = Left
16 atrial; PWA = Posterior wall ablation

17 *Figure 3: Procedure overview*

18 Overview and procedural details for posterior wall ablation using PFA in 215
19 patients. A) Number of cases for each indication. B) Extra-pulmonary vein targets
20 additional to PWA for each indication. Substrate ablation denotes the elimination of
21 additional atrial tachycardia originating from a scar area that is not amenable to
22 linear ablation. C) and D) Differences in procedure duration and X-ray time. LA = Left
23 atrium; CTI = Cavotricuspid isthmus; MIL = Mitral isthmus line; PFA = Pulsed-field
24 ablation; PWA = Posterior wall ablation; SVC = Superior vena cava.

1 *Figure 4: K-M analysis*


2 Outcome after posterior wall ablation using pulsed-field ablation in 215 patients. No
3 difference in arrhythmia-free outcome was found for persistent AF vs. paroxysmal AF
4 patients, for patients with vs. without posterior wall scar, and for performing PWA
5 during the first vs. during a redo procedure. AF = Atrial fibrillation; PWA = Posterior
6 wall ablation.

7

ACCEPTED MANUSCRIPT

Workflow for posterior wall ablation using pulsed field ablation

Step 1: 2x2 Anchor lesions per vein with wired veins and posterior torque (A)



Step 2: Pairwise overlapping applications to cover the entire PW (B)




Figure 1
167x154 mm (x DPI)

1
2
3
4




Figure 2
161x147 mm (x DPI)

1
2
3
4

Posterior wall ablation using PFA – Procedure overview for different indications




Figure 3
305x203 mm (x DPI)

1
2
3
4




Figure 4
254x229 mm (x DPI)

1
2
3